 Accelerating Our Growth © 2007 Endo Pharmaceuticals ENDO PHARMACEUTICALS Annual Meeting of Stockholders May 30, 2007 Exhibit 99.1 |
 Accelerating Our Growth © 2007 Endo Pharmaceuticals Forward-Looking Statements Except for the historical information contained herein, this presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because these statements involve a number of risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the difficulty of predicting FDA approvals, results of clinical trials on new products, acceptance and demand for new pharmaceutical products, challenges relating to intellectual property protection, the impact of competitive products and pricing, the timely development and launch of new products, a determination that we are engaging in inappropriate sales or marketing activities, including promoting the "off-label" use of our products, and the risk factors listed from time to time in the Company’s SEC reports, including the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2006. |
 Accelerating Our Growth © 2007 Endo Pharmaceuticals Endo Pharmaceuticals – Leader in Pain Management Specialty pharma company with market leadership in pain management • Analgesics are the fourth-largest prescription drug market in 2006 • Opioids represented 80% of analgesic prescriptions Proven commercial capability • Specialty and PCP sales and marketing teams Pipeline focused on delivery and execution • Two NDAs approved in 2006; expect additional sNDA in Aug. ‘07 Strong financial condition |
 Accelerating Our Growth © 2007 Endo Pharmaceuticals Growth Strategy Maximize value of established brands Expand through licensing and acquisition while remaining true to our specialty roots • Revenue diversification • Expand balanced, sustainable pipeline Strengthen leadership position in Pain Management and drive continued expansion into additional therapeutic areas such as neurology and supportive care oncology |
 Accelerating Our Growth © 2007 Endo Pharmaceuticals 2006 – Key Accomplishments Secured two NDA approvals Launched three products - Opana ® ER, Opana ® and Synera ® Expanded sales force by 60% to 590 to support new product launches and maintain coverage of existing products Acquired RxKinetix and its supportive care oncology pipeline Filed sNDA for Frova ® for short-term prevention of menstrual migraine Settled OxyContin patent litigation |
 Accelerating Our Growth © 2007 Endo Pharmaceuticals 2007 – Investing in the Future Increasing promotional support behind key brands: • Expanded managed markets team • Expanded clinical liaison team • Conducting comprehensive physician education and patient outreach programs Optimizing expanded sales force of 590 representatives Accelerating R&D investment behind ketoprofen patch, Rapinyl TM , EN 3285, and sufentanil patch Enhancing infrastructure to sustain our growth through 2010: • New systems, processes, people • New building at Chadds Ford headquarters |
 Accelerating Our Growth © 2007 Endo Pharmaceuticals 2007 Key Objectives Achieve $1.025 to $1.050 billion in net sales • Deepen Lidoderm ® penetration in PHN market – Guidance of $650MM to $675MM • Accelerate sales trajectory for the Opana ® franchise – Guidance of $85MM to $105MM Obtain FDA approval for Frova ® in the MM prophylaxis indication Accelerate development of our current pipeline to meet market needs and optimize target product profiles Pursue strategic licensing and acquisition opportunities that expand beyond pain but allow us to retain our focus on the specialty physician community |
 Accelerating Our Growth © 2007 Endo Pharmaceuticals $0 $200 $400 $600 $800 $1,000 $1,200 2002 2003 2004 2005 2006 2007* Net Sales Net Income Consistent Financial Growth $399.0 $595.6 $615.1 $820.2 $30.8 $69.8 $143.3 $202.3 $909.7 $1,037.0 $137.8 (millions, except per share) Diluted EPS $0.30 $0.53 $1.08 $1.52 $1.03** * Represents mid-point of company guidance ** Includes $0.62 in one-time, non-cash items |
 Accelerating Our Growth © 2007 Endo Pharmaceuticals Lidoderm ® - A True Success Story Lidocaine 5% topical patch • Acts locally - no therapeutically meaningful blood levels First FDA-approved drug for treatment of pain of PHN Provides analgesia (but no anesthesia) directly to affected nerves Easy and convenient to use |
 Accelerating Our Growth © 2007 Endo Pharmaceuticals Lidoderm ® - Barriers to Potential Generics Currently protected by five (5) Orange Book-listed patents until 2015: • Two method of use patents expiring 2009 • Two method of use patents expiring 2012 • Formulation patent expiring 2015 2012 method of use patents cover use of lidocaine-containing patch in indication of PHN Lidocaine-containing topical product that does not numb the skin • Unique attribute covered under patent estate • Believe this would be requirement for generic substitution Submitted Citizen Petition December 19, 2006 • Requests that FDA apply existing bioequivalence regulations for topical products to any generic challenger |
 Accelerating Our Growth © 2007 Endo Pharmaceuticals $178 $309 $419 $663 $567 $0 $200 $400 $600 $800 2003 2004 2005 2006 2007* Lidoderm ® - Continuing Net Sales Growth ($ in millions) * Represents mid-point of company guidance |
 Accelerating Our Growth © 2007 Endo Pharmaceuticals Opana ® Franchise |
 Accelerating Our Growth © 2007 Endo Pharmaceuticals Opana ® ER – Broad Label Broad indication: For the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time First time oxymorphone available in oral ER formulation Proven efficacy in broad range of appropriate pain patients Key messages of clinical differentiation • Twice-daily dosing • Effective pain control shown at stable dose for three months in clinical trials underscores durability of Opana ® ER’s analgesic effect • Generally well tolerated when titrated effectively* * Most common adverse events (> 10%) in trials were nausea, constipation, dizziness, vomiting, pruritus, somnolence, headache, increased sweating, and sedation |
 Accelerating Our Growth © 2007 Endo Pharmaceuticals Opana ® Franchise - Targeted Commercial Strategy Opana ® ER competes in $3.2 billion U.S. long-acting strong opioid market Combined Opana ® ER and Opana ® net sales guidance for 2007 is $85 million to $105 million • Expect to reach 10,000 Rx’s per week by year-end Expanded sales force in mid-2006 by 220 reps to promote Opana ® ER and Opana ® to approximately 90,000 physicians Risk Minimization Action Plan implemented for appropriate patient utilization Full range of promotional activities now underway |
 Accelerating Our Growth © 2007 Endo Pharmaceuticals Key Opana ® Marketing and Promotional Activities Instituted Specialty Force II to provide double coverage on 6,600 high- decile specialists Expanded appropriate patient access through direct-discount programs Instituted managed care contracting strategy to achieve parity or better formulary status • Tripled size of managed markets group to extend reach to regional and local plans Introduced new sales/marketing initiatives • Journal ads • Reprints of peer-reviewed journal articles • Speaker dinner programs • Major commercial presence at key medical meetings |
 Accelerating Our Growth © 2007 Endo Pharmaceuticals Opana ® ER TRx Launch Comparison |
 Accelerating Our Growth © 2007 Endo Pharmaceuticals Frova ® Profile Triptan indicated for acute treatment of migraine headaches in adults Market differentiation based on low recurrence rate, long half-life Potential label expansion for menstrual migraine prophylaxis represents significant market opportunity 2006 Net sales $40.6 million |
 Accelerating Our Growth © 2007 Endo Pharmaceuticals Robust Development Pipeline (1) Licensed marketing rights (2) Licensed marketing and development rights Phase I Phase II Phase III Filed Pre- clinical Undisclosed Sufentanil Patch (2) (Transdermal - Chronic Pain) EN 3285 (Oral Rinse for Oral Mucositis) Rapinyl TM (2) (Breakthrough Cancer Pain) Ketoprofen Patch (2) (Topical - Soft Tissue Injuries) Frova ® (Menstrual Migraine) (1) Product |
 Accelerating Our Growth © 2007 Endo Pharmaceuticals Upcoming Key Milestones Expanding a solid platform for sustainable growth: Sufentanil Patch Phase II Ketoprofen Patch NDA Filing Opana ® and Opana ® ER Launch EN 3285 Phase II/III Acquisitions/ In-licensing Rapinyl™ NDA Filing Ongoing 1H’07 2H’07 1H’08 Frova ® MM FDA Action Letter |
 Accelerating Our Growth © 2007 Endo Pharmaceuticals Summary Market leader in pain management Well-developed commercial capability Very broad and deep pipeline Strong financial condition Sustainable strategy for growth |
 Accelerating Our Growth © 2007 Endo Pharmaceuticals ENDO PHARMACEUTICALS Nasdaq: ENDP |